株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

有毛細胞白血病:パイプライン製品の分析

Hairy Cell Leukemia - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 253659
出版日 ページ情報 英文 93 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
有毛細胞白血病:パイプライン製品の分析 Hairy Cell Leukemia - Pipeline Review, H2 2016
出版日: 2016年10月30日 ページ情報: 英文 93 Pages
概要

有毛細胞白血病は、緩慢な経過を示す、希少な血液の癌で、骨髄がB細胞(リンパ球)を過剰に作るようになります。疲労、あざができやすい、感染症を再発、虚弱、体重減少などの症状が見られます。危険因子は、放射線・化学物質への暴露などが含まれます。治療は、外科手術、化学療法、放射線療法などが行われます。

当レポートでは、有毛細胞白血病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

有毛細胞白血病の概要

治療薬の開発

  • パイプライン製品の概要

有毛細胞白血病:企業で開発中の治療薬

有毛細胞白血病:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

有毛細胞白血病:企業で開発中の製品

有毛細胞白血病の治療薬開発に従事している企業

  • AbbVie Inc.
  • アステラス製薬
  • AstraZeneca Plc
  • Biogenomics Limited
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Juno Therapeutics Inc.
  • MedImmune, LLC
  • Novartis AG

有毛細胞白血病:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

有毛細胞白血病:最近のパイプライン動向

有毛細胞白血病:休止中のプロジェクト

有毛細胞白血病:開発が中止された製品

有毛細胞白血病:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8630IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2016, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 1, 1, 2 and 1 respectively.Hairy Cell Leukemia.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Hairy Cell Leukemia Overview
  • Therapeutics Development
    • Pipeline Products for Hairy Cell Leukemia - Overview
  • Hairy Cell Leukemia - Therapeutics under Development by Companies
  • Hairy Cell Leukemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hairy Cell Leukemia - Products under Development by Companies
  • Hairy Cell Leukemia - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • ARA Healthcare Pvt. Ltd.
    • Astellas Pharma Inc.
    • Biogenomics Limited
    • F. Hoffmann-La Roche Ltd.
    • Incyte Corporation
    • Juno Therapeutics Inc.
    • MedImmune LLC
    • Novartis AG
  • Hairy Cell Leukemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dezapelisib + itacitinib adipate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGS-67E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARABS-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dezapelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-50465 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JCAR-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • moxetumomab pasudotox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vemurafenib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hairy Cell Leukemia - Dormant Projects
  • Hairy Cell Leukemia - Discontinued Products
  • Hairy Cell Leukemia - Product Development Milestones
    • Featured News & Press Releases
      • Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumors
      • May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hairy Cell Leukemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Hairy Cell Leukemia - Pipeline by AbbVie Inc, H2 2016
  • Hairy Cell Leukemia - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016
  • Hairy Cell Leukemia - Pipeline by Astellas Pharma Inc., H2 2016
  • Hairy Cell Leukemia - Pipeline by Biogenomics Limited, H2 2016
  • Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Hairy Cell Leukemia - Pipeline by Incyte Corporation, H2 2016
  • Hairy Cell Leukemia - Pipeline by Juno Therapeutics Inc., H2 2016
  • Hairy Cell Leukemia - Pipeline by MedImmune LLC, H2 2016
  • Hairy Cell Leukemia - Pipeline by Novartis AG, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hairy Cell Leukemia - Dormant Projects, H2 2016
  • Hairy Cell Leukemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hairy Cell Leukemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top